News
Media
Between the LinesExpert InterviewsK-CastMedical World NewsPodcastsPopulation Health Perspectives
Conferences
Partners
More
Publications
All PublicationsMHE PublicationFormulary Watch SupplementsFormulary Watch SpotlightsSupplements And Featured Publications
Events
Webinars
CME/CE
Resources
PBMI InnovatorsEmerging LeadersInteractive ToolsSponsored Content
PBM Directory

Subscribe

  • News
  • Media
  • Conferences
  • Partners
  • Publications
  • Events
  • CME/CE
  • Resources
  • PBM Directory
  • Subscribe
  • Asthma
  • Atrial Fibrillation
  • Autoimmune Diseases
  • Biologics
  • Biosimilars
  • Blood Cancer
  • Breast Cancer
  • COVID-19
  • Cardiovascular Diseases
  • Depression
  • Dermatology
  • Diabetes
  • Digital Health
  • Drug Coverage
  • Duchenne Muscular Dystrophy
  • Eyecare
  • FDA
  • Friedreich Ataxia
  • Gene Therapy
  • Graft Versus Host Disease
  • HIV
  • Health Systems
  • Heart Failure
  • Hemophilia
  • Hypertrophic Cardiomyopathy (HCM)
  • Infectious Disease
  • Leukemia and Lymphoma
  • Liver Disease
  • Lung Cancer
  • Mental Health
  • Multiple Sclerosis
  • NSCLC
  • Neonatal Care
  • Nephrology
  • Obstetrics-Gynecology & Women's Health
  • Oncology
  • Oncology Biomarkers
  • Opioids
  • PTSD
  • Pain
  • Pediatrics
  • Plaque Psoriasis
  • Population Health
  • Post-Acute Care
  • Prescription Digital Therapeutics
  • Pulmonary Arterial Hypertension
  • RSV
  • Reproductive Health
  • Respiratory Conditions
  • Safety & Recalls
  • Schizophrenia
  • Shingles
  • Skin Cancer
  • Sleep Disorders
  • Solid Tumors
  • Spinal Muscular Atrophy
  • Substance Use Disorder
  • The Improving Patient Access Podcast
  • Type I Diabetes
  • Type II Inflammation
  • Ulcerative Colitis
  • Uro-Oncology
  • Urothelial Carcinoma
  • Vaccines
  • Women's Health
Spotlight -
AMCP Nexus 2025|
2025 Fall Clinical Dermatology|
AAO 2025|
PBMI 2025|
ASRS 2025|
Between the Lines: Diving Deeper Into the EMERALD Trial
Advertisement

Kirsten Stryker Blasch

Advertisement

Articles by Kirsten Stryker Blasch

CMS’ RADV Strategy Will Reverberate Throughout Health Plan Operations

ByEric Levine, M.P.H.,Tom Martin, M.A., MBA,Mark Newsom, M.Sc.,Kirsten Stryker Blasch
June 30th 2025

To prepare for CMS’ new risk adjustment data validation (RADV) strategy, Medicare Advantage plans must take a coordinated, organization-wide approach.

Advertisement

Latest Updated Articles

  • CMS’ RADV Strategy Will Reverberate Throughout Health Plan Operations
    CMS’ RADV Strategy Will Reverberate Throughout Health Plan Operations

    Published: June 30th 2025 | Updated:



Advertisement
Advertisement

Trending on Managed Healthcare Executive

1

PBM Reform Debate: Panelists Clash Over Spread Pricing and Rebates | AMCP Nexus 2025

2

Cigna Announces ‘Rebate-Free’ Pharmacy Benefit Model Starting in 2027

3

Rebates Play a Major Role in Whether Health Plans Restrict Access to Specialty Drugs | AMCP Nexus 2025

4

Paul Ryan Proposes Risk Pools and Medicare Overhaul to Reform Healthcare | AMCP Nexus 2025

5

Drug Pricing Not Main Driver of State Medicaid Spending | AMCP Nexus 2025

  • About Us
  • Advertise
  • Editorial
  • Contact Us
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Personal Information
Contact Info

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512

609-716-7777

  • Formulary Watch
  • Pharmacy Benefit Management Institute
Managed Healthcare Executive
Brand Logo

© 2025 MJH Life Sciences®

All rights reserved.

Home
About Us
News
Contact Us